Literature DB >> 32350073

Virologic and Immunologic Features of Simian Immunodeficiency Virus Control Post-ART Interruption in Rhesus Macaques.

Zachary Strongin1, Luca Micci1, Rémi Fromentin2,3, Justin Harper1, Julia McBrien1, Emily Ryan1, Neeta Shenvi4, Kirk Easley4, Nicolas Chomont2,3, Guido Silvestri1,5, Mirko Paiardini6,5.   

Abstract

Antiretroviral therapy (ART) cannot eradicate human immunodeficiency virus (HIV) and a rapid rebound of virus replication follows analytical treatment interruption (ATI) in the vast majority of HIV-infected individuals. Sustained control of HIV replication without ART has been documented in a subset of individuals, defined as posttreatment controllers (PTCs). The key determinants of post-ART viral control remain largely unclear. Here, we identified 7 SIVmac239-infected rhesus macaques (RMs), defined as PTCs, who started ART 8 weeks postinfection, continued ART for >7 months, and controlled plasma viremia at <104 copies/ml for up to 8 months after ATI and <200 copies/ml at the latest time point. We characterized immunologic and virologic features associated with post-ART SIV control in blood, lymph node (LN), and colorectal (RB) biopsy samples compared to 15 noncontroller (NC) RMs. Before ART initiation, PTCs had higher CD4 T cell counts, lower plasma viremia, and SIV-DNA content in blood and LN compared to NCs, but had similar CD8 T cell function. While levels of intestinal CD4 T cells were similar, PTCs had higher frequencies of Th17 cells. On ART, PTCs had significantly lower levels of residual plasma viremia and SIV-DNA content in blood and tissues. After ATI, SIV-DNA content rapidly increased in NCs, while it remained stable or even decreased in PTCs. Finally, PTCs showed immunologic benefits of viral control after ATI, including higher CD4 T cell levels and reduced immune activation. Overall, lower plasma viremia, reduced cell-associated SIV-DNA, and preserved Th17 homeostasis, including at pre-ART, are the main features associated with sustained viral control after ATI in SIV-infected RMs.IMPORTANCE While effective, antiretroviral therapy is not a cure for HIV infection. Therefore, there is great interest in achieving viral remission in the absence of antiretroviral therapy. Posttreatment controllers represent a small subset of individuals who are able to control HIV after cessation of antiretroviral therapy, but characteristics associated with these individuals have been largely limited to peripheral blood analysis. Here, we identified 7 SIV-infected rhesus macaques that mirrored the human posttreatment controller phenotype and performed immunologic and virologic analysis of blood, lymph node, and colorectal biopsy samples to further understand the characteristics that distinguish them from noncontrollers. Lower viral burden and preservation of immune homeostasis, including intestinal Th17 cells, both before and after ART, were shown to be two major factors associated with the ability to achieve posttreatment control. Overall, these results move the field further toward understanding of important characteristics of viral control in the absence of antiretroviral therapy.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  HIV-1; PTC; SIV; Th17; analytic treatment interruption; posttreatment controller; viral rebound

Mesh:

Substances:

Year:  2020        PMID: 32350073      PMCID: PMC7343203          DOI: 10.1128/JVI.00338-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.

Authors:  T W Chun; L Carruth; D Finzi; X Shen; J A DiGiuseppe; H Taylor; M Hermankova; K Chadwick; J Margolick; T C Quinn; Y H Kuo; R Brookmeyer; M A Zeiger; P Barditch-Crovo; R F Siliciano
Journal:  Nature       Date:  1997-05-08       Impact factor: 49.962

2.  Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV.

Authors:  Stephen A Migueles; Mark Connors
Journal:  JAMA       Date:  2010-07-14       Impact factor: 56.272

3.  Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques.

Authors:  Gregory Q Del Prete; Rebecca Shoemaker; Kelli Oswald; Abigail Lara; Charles M Trubey; Randy Fast; Douglas K Schneider; Rebecca Kiser; Vicky Coalter; Adam Wiles; Rodney Wiles; Brandi Freemire; Brandon F Keele; Jacob D Estes; Octavio A Quiñones; Jeremy Smedley; Rhonda Macallister; Rosa I Sanchez; John S Wai; Christopher M Tan; W Gregory Alvord; Daria J Hazuda; Michael Piatak; Jeffrey D Lifson
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

4.  Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV-infected patients.

Authors:  A Kök; L Hocqueloux; H Hocini; M Carrière; L Lefrou; A Guguin; P Tisserand; H Bonnabau; V Avettand-Fenoel; T Prazuck; S Katsahian; P Gaulard; R Thiébaut; Y Lévy; S Hüe
Journal:  Mucosal Immunol       Date:  2014-07-02       Impact factor: 7.313

5.  Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems.

Authors:  R Hofmann-Lehmann; R K Swenerton; V Liska; C M Leutenegger; H Lutz; H M McClure; R M Ruprecht
Journal:  AIDS Res Hum Retroviruses       Date:  2000-09-01       Impact factor: 2.205

6.  Changes in the risk of death after HIV seroconversion compared with mortality in the general population.

Authors:  Krishnan Bhaskaran; Osamah Hamouda; Mette Sannes; Faroudy Boufassa; Anne M Johnson; Paul C Lambert; Kholoud Porter
Journal:  JAMA       Date:  2008-07-02       Impact factor: 56.272

7.  HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.

Authors:  Cécile Goujard; Isabelle Girault; Christine Rouzioux; Camille Lécuroux; Christiane Deveau; Marie-Laure Chaix; Christine Jacomet; Amel Talamali; Jean-François Delfraissy; Alain Venet; Laurence Meyer; Martine Sinet
Journal:  Antivir Ther       Date:  2012-08-06

8.  Loss of mucosal CD103+ DCs and IL-17+ and IL-22+ lymphocytes is associated with mucosal damage in SIV infection.

Authors:  N R Klatt; J D Estes; X Sun; A M Ortiz; J S Barber; L D Harris; B Cervasi; L K Yokomizo; L Pan; C L Vinton; B Tabb; L A Canary; Q Dang; V M Hirsch; G Alter; Y Belkaid; J D Lifson; G Silvestri; J D Milner; M Paiardini; E K Haddad; J M Brenchley
Journal:  Mucosal Immunol       Date:  2012-05-30       Impact factor: 7.313

9.  Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy.

Authors:  Maria Salgado; S Alireza Rabi; Karen A O'Connell; Robert W Buckheit; Justin R Bailey; Amina A Chaudhry; Autumn R Breaud; Mark A Marzinke; William Clarke; Joseph B Margolick; Robert F Siliciano; Joel N Blankson
Journal:  Retrovirology       Date:  2011-12-05       Impact factor: 4.602

10.  CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART.

Authors:  Rémi Fromentin; Wendy Bakeman; Mariam B Lawani; Gabriela Khoury; Wendy Hartogensis; Sandrina DaFonseca; Marisela Killian; Lorrie Epling; Rebecca Hoh; Elizabeth Sinclair; Frederick M Hecht; Peter Bacchetti; Steven G Deeks; Sharon R Lewin; Rafick-Pierre Sékaly; Nicolas Chomont
Journal:  PLoS Pathog       Date:  2016-07-14       Impact factor: 6.823

View more
  6 in total

Review 1.  Challenges and Promise of Human Immunodeficiency Virus Remission.

Authors:  Yijia Li; Abbas Mohammadi; Jonathan Z Li
Journal:  J Infect Dis       Date:  2021-02-15       Impact factor: 5.226

2.  IL-21 and IFNα therapy rescues terminally differentiated NK cells and limits SIV reservoir in ART-treated macaques.

Authors:  Justin Harper; Nicolas Huot; Michaela Müller-Trutwin; Mirko Paiardini; Luca Micci; Gregory Tharp; Colin King; Philippe Rascle; Neeta Shenvi; Hong Wang; Cristin Galardi; Amit A Upadhyay; Francois Villinger; Jeffrey Lifson; Guido Silvestri; Kirk Easley; Beatrice Jacquelin; Steven Bosinger
Journal:  Nat Commun       Date:  2021-05-17       Impact factor: 14.919

3.  Predicting Post-treatment HIV Remission: Does Size of the Viral Reservoir Matter?

Authors:  Alexander O Pasternak; Christina K Psomas; Ben Berkhout
Journal:  Front Microbiol       Date:  2021-02-26       Impact factor: 5.640

4.  CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection.

Authors:  Mary S Pampusch; Hadia M Abdelaal; Emily K Cartwright; Jhomary S Molden; Brianna C Davey; Jordan D Sauve; Emily N Sevcik; Aaron K Rendahl; Eva G Rakasz; Elizabeth Connick; Edward A Berger; Pamela J Skinner
Journal:  PLoS Pathog       Date:  2022-02-07       Impact factor: 6.823

5.  Effects of therapeutic vaccination on the control of SIV in rhesus macaques with variable responsiveness to antiretroviral drugs.

Authors:  Hillary Claire Tunggal; Paul Veness Munson; Megan Ashley O'Connor; Nika Hajari; Sandra Elizabeth Dross; Debra Bratt; James Thomas Fuller; Kenneth Bagley; Deborah Heydenburg Fuller
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

Review 6.  How elite controllers and posttreatment controllers inform our search for an HIV-1 cure.

Authors:  Jonathan Z Li; Joel N Blankson
Journal:  J Clin Invest       Date:  2021-06-01       Impact factor: 19.456

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.